Relief Therapeutics Holding SA (RLF) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Relief Therapeutics Holding SA

Home
Companies
Relief Therapeutics Holding SA

BRIEF

published on 11/11/2024 at 07:05, 10 days 3 hours ago

Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa

Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE

published on 11/11/2024 at 07:00, 10 days 3 hours ago

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements

Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF

published on 11/04/2024 at 07:05, 17 days 3 hours ago

Relief Therapeutics and Renexxion Consider Reverse Merger

Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
PRESS RELEASE

published on 11/04/2024 at 07:00, 17 days 3 hours ago

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics signs non-binding letter of intent with Renexxion for reverse merger, aiming to create a combined entity with an expanded therapeutic pipeline

Biopharmaceutical Relief Therapeutics Therapeutic Pipeline Reverse Merger Renexxion
BRIEF

published on 10/29/2024 at 07:05, 23 days 3 hours ago

Relief Therapeutics Highlights PKU GOLIKE Findings

Patient Engagement Relief Therapeutics PKU GOLIKE Phenylketonuria Amino Acid Absorption
PRESS RELEASE

published on 10/29/2024 at 07:00, 23 days 3 hours ago

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics announced the publication of a Plain Language Summary on PKU GOLIKE for phenylketonuria management, highlighting findings on prolonged-release protein substitute with similarities to natural proteins

Medical Research Relief Therapeutics PKU GOLIKE Phenylketonuria Plain Language Summary
BRIEF

published on 10/25/2024 at 07:05, 27 days 3 hours ago

Relief Therapeutics Unveils Promising Study Results for RLF-OD032

Clinical Study Patent Filing RLF-OD032 Phenylketonuria Drug Absorption
PRESS RELEASE

published on 10/25/2024 at 07:00, 27 days 3 hours ago

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics reports positive study results for RLF-OD032, showing superior absorption in fasted state compared to KUVAN®, enabling flexible dosing. New patents filed for innovative PKU treatment

Study Results Relief Therapeutics RLF-OD032 Phenylketonuria Provisional Patents
BRIEF

published on 10/21/2024 at 07:05, 1 month ago

Relief Therapeutics Secures European Patent for RLF-TD011

Orphan Drug Designation Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE

published on 10/21/2024 at 07:00, 1 month ago

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets

Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa Wound Treatment

Accesswire

Published on 11/21/2024 at 10:03, 29 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 32 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 32 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 57 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 7 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 27 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 30 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 32 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 32 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 31 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 34 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 12 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 47 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 47 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE